Toxicology – Hearing Abnormalities

Definition

Toxic exposures and medications can produce auditory abnormalities, most commonly:

• Tinnitus – perception of ringing, buzzing, or other sound without an external source
• Hearing loss – partial or complete reduction in hearing

Drug-induced hearing loss is usually sensorineural, although conductive and central auditory disorders have other important causes.

Normal Hearing

Sound transmission occurs through:

Sound waves → tympanic membrane → ossicles → cochlear fluid movement → organ of Corti hair cells → cochlear nerve (CN VIII) → auditory cortex

Damage anywhere along this pathway can impair hearing.

Conductive vs. Sensorineural Hearing Loss

Conductive hearing loss

Results from impaired transmission through the:

• External auditory canal
• Tympanic membrane
• Middle ear

Examples include:

• Cerumen impaction
• Foreign body
• Otitis media
• Tympanic membrane injury
• Otosclerosis

Sensorineural hearing loss

Results from injury to:

• Cochlear hair cells
• Stria vascularis
• Cochlear nerve
• Central auditory pathways

Potential causes include:

• Ototoxic medications
• Excessive noise exposure
• Infection
• Aging
• Vascular disease
• Temporal bone injury
• Vestibular schwannoma
• Toxic chemical exposure

Major Ototoxic Drugs

Important medications associated with tinnitus or hearing impairment include:

Aminoglycosides

• Gentamicin
• Tobramycin
• Amikacin
• Streptomycin
• Neomycin

These can produce cochlear and/or vestibular toxicity.

Risk increases with:

• Higher cumulative exposure
• Renal dysfunction
• Concurrent ototoxic medications

Hearing injury can be irreversible.

Platinum Chemotherapy

Cisplatin is an important cause of:

• Bilateral sensorineural hearing loss
• High-frequency hearing impairment
• Tinnitus

Ototoxicity may be cumulative and permanent.

Salicylates

Salicylate toxicity commonly causes:

• Tinnitus
• Reduced hearing
• Nausea/vomiting
• Tachypnea
• Acid-base abnormalities

The auditory abnormalities are generally reversible after salicylate concentrations fall.

Key Point: Improvement or disappearance of tinnitus does not reliably prove that systemic salicylate toxicity has resolved.

Quinine and Quinidine

These may produce cinchonism, characterized by:

• Tinnitus
• Hearing impairment
• Headache
• Nausea
• Visual disturbances

Severe poisoning can additionally cause cardiovascular toxicity.

Loop Diuretics

Examples include:

• Furosemide
• Bumetanide
• Ethacrynic acid

Ototoxicity is particularly associated with:

• Rapid IV administration
• High exposure
• Renal dysfunction
• Concurrent ototoxic medications

Hearing impairment is often reversible but can occasionally persist.

Other Potentially Ototoxic Agents

Reported associations include:

• Macrolide antibiotics
• Chloroquine and related agents
• Deferoxamine
• Some NSAIDs
• Metronidazole
• Selected local anesthetics
• Certain industrial solvents
• Heavy metals

Not every reported association carries the same strength of evidence or risk.

Toxic Chemical Causes

Organic mercury

May produce:

• Hearing impairment
• Visual-field abnormalities
• Ataxia
• Dysarthria
• Tremor
• Sensory disturbances

Lead

Chronic exposure can produce neurologic abnormalities and has been associated with auditory dysfunction, particularly with significant or prolonged exposure.

Solvents

Some occupational solvents, including toluene, can contribute to sensorineural hearing impairment, particularly with chronic exposure and concurrent noise exposure.

Carbon Monoxide and Cyanide

Severe cellular hypoxia can injure auditory pathways.

Hearing abnormalities have occasionally been reported following recovery from severe:

• Carbon monoxide poisoning
• Cyanide poisoning

In these cases, auditory injury may become apparent after the initial life-threatening toxicity has resolved.

Bromate

Significant bromate poisoning can produce:

• Vomiting and diarrhea
• Acute kidney injury
• Sensorineural hearing loss

Hearing impairment may be permanent.

Clinical Assessment

Important history includes:

• Onset: sudden vs. gradual
• Unilateral vs. bilateral symptoms
• Tinnitus vs. hearing loss
• Medication exposure
• Recent overdose
• Occupational chemical exposure
• Noise exposure
• Renal impairment
• Ear infection or trauma
• Associated vestibular symptoms

Medication review is particularly important because multiple ototoxic drugs may have additive effects.

Associated Findings

Certain combinations provide diagnostic clues.

Tinnitus + tachypnea + vomiting + acid-base disturbance

→ consider salicylate toxicity

Hearing loss + renal injury during antimicrobial treatment

→ consider aminoglycoside toxicity

Hearing loss during cisplatin therapy

→ consider platinum-associated ototoxicity

Tinnitus + visual disturbances

→ consider quinine/quinidine toxicity

Hearing impairment + ataxia/tremor/visual abnormalities

→ consider organic mercury exposure

Physical Examination

Assess:

• External auditory canal
• Tympanic membrane
• Evidence of infection
• Cerumen or foreign body
• Neurologic examination
• Cranial nerves
• Vestibular findings when relevant

Bedside hearing tests can help distinguish conductive from sensorineural loss.

Weber Test

A vibrating tuning fork is placed on the midline of the skull.

Normal

• Sound is heard approximately equally in both ears.

Unilateral conductive hearing loss

• Sound lateralizes toward the affected ear.

Unilateral sensorineural hearing loss

• Sound lateralizes toward the better/unaffected ear.

Rinne Test

The test compares air conduction (AC) with bone conduction (BC).

Normally:

AC > BC

Conductive hearing loss

• Bone conduction becomes greater than air conduction in the affected ear.

Sensorineural hearing loss

• Air conduction generally remains greater than bone conduction, but overall hearing is reduced.

A 512-Hz tuning fork is generally preferred for modern bedside Weber and Rinne testing rather than the 256-Hz fork described in older references.

Audiologic Evaluation

Formal assessment may include:

• Pure-tone audiometry
• Speech audiometry
• Tympanometry
• Otoacoustic emissions
• Auditory brainstem response testing

Audiometry is especially useful for detecting and monitoring medication-associated ototoxicity.

Laboratory Evaluation

Testing should be directed toward the suspected cause.

Possible investigations include:

• Renal function
• Electrolytes
• Salicylate concentration
• Specific medication concentrations when clinically useful
• Heavy-metal testing when exposure is plausible
• Acid-base evaluation in systemic poisoning

Routine broad toxicology screening is usually less useful than targeted testing.

Imaging

Imaging is determined by the clinical pattern.

Unilateral or asymmetric sensorineural hearing loss

may warrant MRI evaluation for retrocochlear pathology such as a vestibular schwannoma.

Temporal-bone imaging may be appropriate when trauma or structural disease is suspected.

Sudden Sensorineural Hearing Loss

Sudden unexplained sensorineural hearing loss should be considered an otologic emergency.

Prompt ENT/audiology evaluation is important because time-sensitive treatment may be indicated for causes unrelated to poisoning.

Do not automatically attribute sudden hearing loss to a medication merely because the patient is taking a potentially ototoxic drug.

Management

Management centers on the underlying cause:

• Stop or modify the suspected ototoxic agent when medically appropriate.
• Treat the underlying poisoning.
• Correct renal or metabolic abnormalities.
• Avoid additional ototoxic exposures when possible.
• Obtain audiology/ENT assessment for persistent or significant abnormalities.

Medication changes should account for the clinical importance of the original treatment; an essential antimicrobial or chemotherapy agent should not simply be discontinued without appropriate specialist input.

Decontamination

Management depends on the route and specific toxicant.

For inhalational exposure:

• Remove the patient from the source.
• Provide appropriate supportive care.

For dermal contamination:

• Remove contaminated clothing when appropriate.
• Irrigate exposed skin according to the chemical involved.

Historical recommendations for routine ipecac or gastric lavage after ingestion are not part of standard modern management.

Prognosis

Recovery depends on the agent and extent of cochlear injury.

Often reversible:

• Salicylate-associated tinnitus/hearing impairment
• Many NSAID-related auditory effects
• Some loop-diuretic-associated hearing abnormalities

Potentially permanent:

• Aminoglycoside ototoxicity
• Cisplatin ototoxicity
• Bromate-associated hearing loss
• Severe cochlear injury from other toxicants

Key Points

• Toxicants most commonly produce sensorineural hearing abnormalities.
• Major ototoxic agents include aminoglycosides, cisplatin, salicylates, quinine/quinidine, and loop diuretics.
• Tinnitus is a classic manifestation of salicylate toxicity, but its disappearance does not prove that the poisoning has resolved.
• Aminoglycoside toxicity is more likely with renal dysfunction and greater cumulative exposure.
• Cisplatin commonly affects high-frequency hearing and may cause permanent injury.
• Weber and Rinne tests help distinguish conductive from sensorineural hearing loss.
• Weber: conductive → affected ear; sensorineural → unaffected ear.
• Rinne: normal/sensorineural = AC > BC; conductive = BC > AC.
• Sudden unexplained sensorineural hearing loss requires prompt specialist evaluation.
• Treatment primarily involves recognizing the responsible agent, treating systemic toxicity, and preventing further ototoxic exposure.

Toxicology – Gulf War Illness

Definition

Gulf War illness (GWI), historically called Gulf War syndrome, is a chronic multisymptom illness occurring in a subset of military personnel who served in the 1990–1991 Persian Gulf War.

Common manifestations involve several systems and include:

• Persistent fatigue
• Cognitive or memory difficulties
• Headache
• Muscle and joint pain
• Sleep disturbance
• Gastrointestinal symptoms
• Respiratory complaints
• Skin symptoms

Modern literature generally prefers the term Gulf War illness because affected veterans have recognizable patterns of chronic symptoms even though there is no single diagnostic laboratory test or universally established mechanism.

Pathophysiology

The pathophysiology remains incompletely understood.

Research has investigated several potentially interacting mechanisms, including:

• Neuroinflammation
• Autonomic nervous system abnormalities
• Immune dysregulation
• Mitochondrial dysfunction
• Neuroendocrine alterations
• Genetic susceptibility interacting with deployment exposures

No single mechanism currently explains every case.

Potential Deployment-Related Exposures

Gulf War personnel encountered a complex mixture of environmental and occupational exposures.

Investigated possibilities include:

• Organophosphate and other pesticides
• Pyridostigmine bromide
• Low-level nerve-agent exposure in some personnel
• Oil-well fire smoke
• Petroleum products and solvents
• Depleted uranium
• Chemical-agent-resistant coatings
• Vaccinations
• Dust and particulate matter
• Psychological and physiologic stress

Evidence supporting a causal relationship is not equally strong for all of these exposures.

Pesticides

Pesticides are among the deployment exposures that have received substantial attention.

Agents used during deployment included various:

• Organophosphate insecticides
• Carbamates
• Pyrethroids
• Insect repellents such as DEET

Organophosphates inhibit acetylcholinesterase and can produce acute cholinergic toxicity at sufficiently high exposure.

Importantly, the absence of an obvious acute cholinergic crisis does not by itself exclude lower-level exposure or establish whether such exposure contributed to later Gulf War illness.

Pyridostigmine Bromide

Pyridostigmine was provided to some Gulf War personnel as a pretreatment intended for use in anticipation of possible nerve-agent exposure.

It reversibly inhibits acetylcholinesterase.

Acute adverse effects can include:

• Abdominal cramping
• Diarrhea
• Increased secretions
• Sweating
• Other cholinergic manifestations

Research has examined whether pyridostigmine, particularly in combination with other deployment exposures, contributed to GWI. This remains an area of scientific investigation rather than a simple single-agent explanation.

Nerve Agents

Possible exposure to organophosphate nerve agents has been extensively investigated.

A particularly important historical event was the 1991 demolition of Iraqi munitions at Khamisiyah, during which some U.S. personnel may have been exposed to low levels of sarin/cyclosarin released into the atmosphere.

High-dose nerve-agent poisoning produces an acute cholinergic syndrome with:

• Miosis
• Bronchorrhea
• Salivation
• Vomiting and diarrhea
• Fasciculations
• Weakness
• Seizures
• Respiratory failure

The relationship between lower-level wartime exposure and chronic Gulf War illness has been the subject of continuing epidemiologic research.

Oil-Well Fires and Combustion Products

Burning Kuwaiti oil wells generated substantial smoke and particulate pollution.

Potential exposures included:

• Particulate matter
• Hydrocarbons
• Carbon monoxide
• Sulfur compounds
• Nitrogen oxides
• Other combustion products

These exposures can produce acute:

• Eye and mucosal irritation
• Cough
• Bronchial irritation
• Exacerbation of underlying respiratory disease

Their contribution to the overall chronic multisymptom illness remains less clearly established than some other proposed exposures.

Depleted Uranium

Depleted uranium exposure occurred particularly among personnel involved with:

• Friendly-fire incidents
• Damaged armored vehicles
• Depleted-uranium munitions

Uranium has both chemical toxicity and weak radioactivity, with the kidney being an important target of sufficiently large systemic exposure.

Research has not established depleted uranium as a general explanation for the broad pattern of Gulf War illness across affected veterans.

Chemical-Agent-Resistant Coatings

Some military equipment was treated with chemical-resistant coatings containing compounds capable of causing occupational toxicity.

Isocyanates, for example, can cause:

• Airway irritation
• Occupational asthma
• Respiratory sensitization

Such exposures may explain particular respiratory problems in exposed individuals but do not by themselves account for the overall GWI syndrome.

Vaccinations

Personnel received multiple vaccines associated with deployment requirements.

Vaccination-related hypotheses have been investigated, but vaccines have not been established as a single general cause of Gulf War illness.

Psychological Stress and PTSD

Combat and deployment stress can produce:

• PTSD
• Anxiety
• Depression
• Sleep disturbance
• Cognitive symptoms
• Physical symptoms

However, Gulf War illness should not simply be equated with PTSD or considered purely psychological.

GWI and PTSD are distinct conditions, although they may coexist in the same individual.

Clinical Features

GWI typically involves symptoms across multiple domains.

Neurologic/Cognitive

• Headache
• Memory difficulties
• Problems with concentration
• Cognitive complaints

General

• Persistent fatigue
• Reduced exercise tolerance

Musculoskeletal

• Muscle pain
• Joint pain

Sleep

• Poor-quality sleep
• Insomnia or other sleep disturbance

Gastrointestinal

• Abdominal symptoms
• Diarrhea
• Other chronic GI complaints

Respiratory

• Cough
• Shortness of breath
• Other respiratory complaints

Dermatologic

• Recurrent or persistent skin symptoms

The exact combination and severity vary considerably between individuals.

Diagnosis

There is no single diagnostic biomarker or laboratory test that confirms Gulf War illness.

Diagnosis is based on:

• Gulf War deployment history
• Characteristic chronic multisystem symptoms
• Duration and functional impact
• Exclusion or identification of alternative explanations

Research and clinical frameworks use symptom-based criteria, including the CDC chronic multisymptom illness definition and the Kansas Gulf War illness criteria.

Differential Diagnosis

Because GWI symptoms are nonspecific, other treatable conditions should be considered rather than attributing every symptom automatically to deployment.

Depending on presentation, alternatives include:

• Thyroid disease
• Anemia
• Sleep disorders
• Chronic infection
• Autoimmune disease
• Neurologic disorders
• Medication adverse effects
• Fibromyalgia
• Chronic fatigue syndromes
• PTSD, depression, or anxiety disorders

These diagnoses may also coexist with GWI.

Laboratory Testing

No characteristic routine laboratory abnormality defines GWI.

Testing should therefore be directed by:

• Symptoms
• Physical examination
• Exposure history
• Relevant differential diagnoses

Broad indiscriminate toxicology testing decades after deployment generally cannot reconstruct historical exposures.

Management

There is no single established antidote or universally effective disease-specific treatment.

Management is individualized and generally focuses on:

• Treating specific symptoms
• Managing sleep disorders
• Addressing chronic pain
• Treating gastrointestinal or respiratory disease when identified
• Physical rehabilitation appropriate to tolerance
• Management of coexisting medical or psychological conditions
• Ongoing clinical follow-up

Treatment should focus on improving function and quality of life while avoiding the assumption that every new symptom necessarily results from GWI.

Decontamination

There is no role for decontamination because the relevant deployment exposures occurred decades ago.

Similarly, empiric chelation or other attempts to remove presumed historical toxicants are not routinely indicated without evidence of a current specific toxic exposure.

Prognosis

The course varies.

Some individuals improve, whereas others experience persistent symptoms lasting many years.

Because GWI is heterogeneous, prognosis depends partly on:

• Symptom pattern
• Severity
• Functional impairment
• Coexisting conditions

Key Points

• Gulf War illness is a chronic multisymptom illness affecting a subset of 1990–1991 Gulf War veterans.
• Common manifestations include fatigue, cognitive problems, musculoskeletal pain, headache, sleep disturbance, and GI symptoms.
• The pathophysiology remains incompletely understood and is probably more complex than exposure to a single toxicant.
• Investigated exposures include pesticides, pyridostigmine bromide, nerve agents, oil-well fire smoke, depleted uranium, and other deployment-related exposures.
• Some personnel may have experienced low-level nerve-agent exposure associated with the Khamisiyah demolitions.
• GWI should not be dismissed as simply PTSD or psychological illness, although PTSD and other psychiatric conditions can coexist.
• There is no single confirmatory laboratory test or biomarker.
• Diagnosis is clinical and requires consideration of other treatable diseases.
• No specific antidote exists; treatment is primarily individualized symptom management and rehabilitation.
• Historical exposure does not justify current decontamination or empiric chelation.

Toxicology – Coma

Definition

Coma is a state of profoundly depressed consciousness in which the patient cannot be appropriately aroused or respond meaningfully to external stimuli.

In toxicology, coma is a clinical syndrome rather than a diagnosis. The immediate priorities are to identify and treat reversible threats to oxygenation, ventilation, circulation, and cerebral metabolism.

Pathophysiology

Major mechanisms that can produce coma include:

• CNS-depressant drugs or toxins
• Hypoxia or inadequate cerebral perfusion
• Hypoglycemia
• Severe electrolyte disturbances
• Acid-base abnormalities
• Hyperthermia or hypothermia
• Structural intracranial disease
• Seizures or postictal states
• Severe systemic infection or metabolic disease

Many different poisons can eventually cause coma, particularly as a preterminal manifestation.

Important Toxicologic Causes

Opioids

• CNS depression
• Respiratory depression
• Miosis
• Reduced bowel sounds

The most immediately dangerous manifestation is hypoventilation.

Sedative-hypnotics

Examples include:

• Benzodiazepines
• Barbiturates
• Ethanol
• Other CNS depressants

Typical findings include:

• Somnolence progressing to coma
• Ataxia before severe CNS depression
• Respiratory depression in severe poisoning

Isolated benzodiazepine overdose usually causes less respiratory depression than combinations with opioids, ethanol, or other sedatives.

Clonidine and imidazolines

• CNS depression
• Miosis
• Bradycardia
• Hypotension
• Respiratory depression

These can mimic opioid poisoning.

Tricyclic antidepressants

Severe toxicity may produce:

• Coma
• Seizures
• Hypotension
• Tachycardia
• QRS widening
• Ventricular dysrhythmias

Anticonvulsants

Many cause:

• Nystagmus
• Ataxia
• Slurred speech
• CNS depression

Severe poisoning can progress to coma.

Cellular Asphyxiants and Toxic Gases

Carbon monoxide

• Headache
• Nausea
• Confusion
• Syncope
• Coma in severe poisoning

Pulse oximetry may appear misleadingly normal.

Cyanide

• Rapid neurologic deterioration
• Cardiovascular collapse
• Severe lactic acidosis

Hydrogen sulfide

• Rapid collapse after major exposure
• Respiratory failure
• Seizures or coma

Multiple simultaneously affected patients can be an important environmental clue.

Toxic Alcohols

Methanol

Early intoxication may resemble ethanol exposure.

Later findings include:

• High-anion-gap metabolic acidosis
• Visual abnormalities
• CNS depression
• Coma

Ethylene glycol

Later toxicity may include:

• High-anion-gap metabolic acidosis
• Hypocalcemia
• Acute kidney injury
• CNS depression

Isopropanol

Typically produces:

• Marked CNS depression
• Ketosis
• GI irritation or hemorrhagic gastritis

Unlike methanol and ethylene glycol, isopropanol classically produces ketosis without a high-anion-gap metabolic acidosis attributable to toxic metabolites.

Clinical Examination

The physical examination should look for a recognizable toxidrome.

Important features include:

• Vital signs
• Respiratory pattern
• Pupils
• Skin temperature and moisture
• Bowel sounds
• Muscle tone
• Reflexes
• Clonus or rigidity
• Evidence of trauma
• Focal neurologic abnormalities

Pupillary Clues

Miosis

• Opioids
• Clonidine/imidazolines
• Cholinergic poisoning

Mydriasis

• Sympathomimetics
• Antimuscarinic agents
• Severe hypoxia
• Some antidepressants and anticonvulsants

Nystagmus

May occur with:

• Ethanol
• Phenytoin
• Carbamazepine
• Sedative-hypnotics
• Dissociative agents such as PCP

Pupil findings are supportive but not diagnostic by themselves.

Vital-Sign Clues

Tachycardia

• Sympathomimetics
• Antimuscarinics
• TCAs and other sodium-channel blockers

Bradycardia

• Beta-blockers
• Calcium-channel blockers
• Clonidine/imidazolines
• Cholinergic agents
• Baclofen

Hyperthermia

• Sympathomimetic toxicity
• Anticholinergic syndrome
• Serotonin syndrome
• Neuroleptic malignant syndrome
• Severe salicylate poisoning

Hypothermia

• Sedative intoxication
• Environmental exposure during prolonged unconsciousness

Respiratory Pattern

Bradypnea/hypoventilation

suggests:

• Opioids
• Sedative-hypnotics
• Clonidine
• Severe CNS depression

Tachypnea/hyperpnea

may occur with:

• Salicylates
• Methanol
• Ethylene glycol
• Metabolic acidosis
• Hypoxia
• Hyperthermia

Respiratory pattern can therefore provide an important clue to the underlying poison.

ECG

An ECG should be obtained early in unexplained toxicologic coma.

Important abnormalities include:

• QRS widening
• QT prolongation
• Bradycardia
• AV block
• Ventricular dysrhythmias

QRS widening with a prominent terminal R wave in aVR can support significant cardiac sodium-channel blockade, classically associated with TCA poisoning, although it is not specific to TCAs.

Laboratory Evaluation

Immediate evaluation commonly includes:

• Bedside glucose
• Electrolytes
• Bicarbonate
• Renal function
• Calcium and magnesium
• ECG
• Oxygenation and ventilation assessment

Depending on circumstances:

• Blood gas
• Serum acetaminophen concentration
• Salicylate concentration
• Ethanol concentration
• Toxic alcohol evaluation
• Specific drug concentrations
• Creatine kinase
• Liver tests

An unexplained high-anion-gap metabolic acidosis should prompt consideration of toxic and nontoxic causes, including toxic alcohols, salicylates, lactic acidosis, and other metabolic disorders.

Urine Drug Screening

Routine urine immunoassay drug screens have important limitations.

A positive result:

• Does not establish current intoxication.
• Does not prove the detected drug caused the coma.

A negative result:

• Does not exclude poisoning.
• May miss many clinically important substances.

Management should therefore be based primarily on the clinical syndrome and targeted testing.

Structural and Nontoxicologic Causes

Do not automatically assume that an unconscious patient is poisoned.

Important alternatives include:

• Intracranial hemorrhage
• Ischemic stroke
• CNS infection
• Seizure/postictal state
• Hypoglycemia
• Severe sodium abnormalities
• Sepsis
• Hepatic or uremic encephalopathy

Focal neurologic abnormalities increase concern for structural CNS disease, but their absence does not completely exclude an intracranial process.

Brain imaging, lumbar puncture, cultures, or other investigations may therefore be necessary depending on the presentation.

Initial Management

Management follows standard resuscitation priorities:

• Ensure airway patency.
• Assess breathing and ventilation.
• Provide oxygen when indicated.
• Assist ventilation when inadequate.
• Establish IV access.
• Monitor cardiac rhythm and vital signs.
• Check bedside glucose immediately.
• Treat seizures and major temperature abnormalities.

Endotracheal intubation is indicated when the patient cannot maintain adequate ventilation or reliably protect the airway.

Naloxone

Naloxone should be given when opioid-induced respiratory depression is suspected.

The goal is restoration of:

• Adequate ventilation
• Adequate airway protection

Complete awakening is not required.

Routine naloxone solely because a patient is unconscious is less useful when there is no evidence of opioid-related respiratory depression.

Glucose and Thiamine

Glucose

Check bedside glucose promptly and treat documented or strongly suspected hypoglycemia immediately.

The older practice of automatically giving concentrated dextrose to every comatose patient has largely been replaced by rapid point-of-care glucose testing.

Thiamine

Thiamine is appropriate when deficiency is suspected, particularly in patients with malnutrition or chronic heavy alcohol use.

When hypoglycemia is present, glucose treatment should not be delayed while waiting to administer thiamine.

Flumazenil

Flumazenil reverses benzodiazepine effects but is not routinely recommended for undifferentiated overdose-associated coma.

It can precipitate seizures or withdrawal, particularly in:

• Chronic benzodiazepine users
• Patients with seizure disorders
• Mixed overdoses
• Coingestion of proconvulsant drugs such as TCAs

Its use is therefore generally restricted to carefully selected circumstances.

Decontamination

Do not induce vomiting in a patient with depressed consciousness.

Older recommendations for routine gastric lavage in comatose overdose patients are obsolete and potentially dangerous.

Activated charcoal may occasionally be appropriate after selected ingestions, but it should not be administered to a patient with impaired airway reflexes unless the airway is adequately protected and the expected benefit justifies its use.

Complications

Important complications of prolonged coma include:

• Aspiration
• Hypoxic brain injury
• Pressure injury
• Rhabdomyolysis
• Acute kidney injury
• Hypothermia
• Venous thromboembolism
• Respiratory failure

Drug Intoxication and Brain Death Assessment

Profound intoxication with certain CNS depressants can closely mimic catastrophic neurologic injury.

Therefore, drug intoxication and other reversible confounders must be adequately excluded before determination of death by neurologic criteria.

An EEG alone is not sufficient to resolve this issue in a deeply intoxicated patient.

Key Points

• Coma is a syndrome, not a diagnosis.
• Stabilize airway, breathing, circulation, and glucose while investigating the cause.
• Miosis + respiratory depression → strongly consider opioids, but clonidine and cholinergic poisoning can mimic this pattern.
• QRS widening + coma/seizures/hypotension → consider sodium-channel-blocking toxicity, including TCAs.
• High-anion-gap metabolic acidosis can provide an important clue to toxic alcohols, salicylates, cyanide-related lactic acidosis, and other toxic/metabolic disorders.
• Naloxone is primarily used to reverse suspected opioid-induced respiratory depression, not simply unconsciousness.
• Flumazenil should not routinely be used in undifferentiated overdose coma.
• Routine urine drug screens cannot reliably identify or exclude the cause of coma.
• Routine gastric lavage in poisoned comatose patients is obsolete.
• Always consider structural neurologic, infectious, metabolic, and toxicologic causes simultaneously.

Toxicology – Cholinergic Syndrome

Definition

Cholinergic syndrome is a toxidrome caused by excessive stimulation of acetylcholine receptors.

The classic syndrome includes:

• Excessive salivation and lacrimation
• Sweating
• Bronchorrhea and bronchospasm
• Miosis
• Vomiting and diarrhea
• Urination
• Bradycardia

Severe poisoning may additionally cause:

• Fasciculations
• Muscle weakness or paralysis
• Altered mental status
• Seizures
• Respiratory failure

Pathophysiology

Many important cholinergic poisons inhibit acetylcholinesterase (AChE), the enzyme responsible for breaking down acetylcholine.

This produces:

AChE inhibition → acetylcholine accumulation → excessive muscarinic + nicotinic + CNS stimulation

The two major peripheral receptor groups produce different manifestations.

Muscarinic Effects

Muscarinic overstimulation produces:

• Miosis
• Salivation
• Lacrimation
• Sweating
• Bronchorrhea
• Bronchospasm
• Bradycardia
• Vomiting
• Abdominal cramping
• Diarrhea
• Urination

A useful mnemonic is DUMBELS:

• D – Defecation/Diarrhea, Diaphoresis
• U – Urination
• M – Miosis
• B – Bronchorrhea, Bronchospasm, Bradycardia
• E – Emesis
• L – Lacrimation
• S – Salivation

Nicotinic Effects

Nicotinic receptor overstimulation at autonomic ganglia and the neuromuscular junction can cause:

• Muscle fasciculations
• Muscle weakness
• Paralysis
• Tachycardia
• Hypertension

Severe neuromuscular weakness can contribute substantially to respiratory failure.

Central Nervous System Effects

Because some cholinesterase inhibitors enter the CNS, severe poisoning may cause:

• Anxiety or agitation
• Confusion
• Altered consciousness
• Seizures
• Coma
• Central respiratory depression

Organophosphates

Organophosphate insecticides are major causes of severe cholinergic poisoning.

They inhibit acetylcholinesterase by phosphorylating the enzyme.

Over time, the organophosphate–AChE complex can undergo “aging,” after which reactivation of the enzyme becomes increasingly difficult.

Recovery then depends substantially on synthesis of new functional enzyme.

Carbamates

Carbamates also inhibit acetylcholinesterase but generally form a reversible carbamylated enzyme complex.

Their toxicity is often shorter-lived than organophosphate poisoning, although severe poisoning can still occur.

Other Causes

Cholinergic manifestations can also occur with:

• Physostigmine
• Neostigmine
• Pyridostigmine
• Bethanechol
• Pilocarpine
• Certain muscarine-containing mushrooms
• Nicotine and related agents, although their receptor effects differ from classic AChE inhibition

Not every cholinergic syndrome is therefore caused by an organophosphate.

Clinical Features

Eyes/HEENT

• Miosis
• Lacrimation
• Salivation
• Blurred vision

Skin

• Profuse sweating

Cardiovascular

• Bradycardia from muscarinic activity
• Tachycardia and hypertension from nicotinic ganglionic activity
• Hypotension
• Dysrhythmias in severe poisoning

The heart rate can therefore be either slow or fast.

Gastrointestinal

• Nausea
• Vomiting
• Abdominal cramping
• Diarrhea
• Increased bowel activity

Neuromuscular

• Fasciculations
• Weakness
• Paralysis

Neurologic

• Confusion
• Seizures
• CNS depression
• Coma

Respiratory Failure

Respiratory compromise is the major immediate threat.

It may result simultaneously from:

• Bronchorrhea
• Bronchospasm
• Central respiratory depression
• Neuromuscular weakness/paralysis
• Aspiration
• Pulmonary edema in severe cases

This combination can cause rapid hypoxemia and respiratory arrest.

Differential Diagnosis

Conditions that can partially resemble cholinergic poisoning include:

Nicotine toxicity

• Nausea/vomiting
• Sweating
• Fasciculations
• Autonomic instability

Opioid poisoning

• Miosis and respiratory depression, but usually without profuse secretions or fasciculations

Sympathomimetic poisoning

• Sweating, tachycardia, hypertension and agitation, but usually mydriasis rather than miosis and without the characteristic bronchorrhea

Beta-blocker, calcium-channel blocker, or digoxin toxicity

• Can cause bradycardia and hypotension but generally lack the characteristic secretory syndrome.

Botulism

• Produces weakness/paralysis but typically causes dryness and descending paralysis, rather than a wet cholinergic syndrome.

Diagnosis

Diagnosis is primarily clinical.

The combination of:

miosis + profuse secretions + bronchorrhea + fasciculations/weakness

strongly suggests significant cholinergic poisoning.

Exposure history should include:

• Pesticides
• Occupational exposure
• Medications
• Plants or mushrooms
• Possible dermal or inhalational exposure

Cholinesterase Testing

Laboratory measurements may include:

Plasma butyrylcholinesterase

• Often readily available
• Sensitive to exposure
• Less closely related to neuromuscular AChE activity

Red blood cell acetylcholinesterase

• More closely reflects neuronal/neuromuscular acetylcholinesterase activity
• May correlate better with significant organophosphate effects

However, treatment of a severely symptomatic patient should not wait for cholinesterase results.

Additional Evaluation

Depending on severity:

• ECG and continuous cardiac monitoring
• Oxygen saturation
• Blood gas when respiratory failure is suspected
• Electrolytes
• Glucose
• Renal function
• Chest imaging when pulmonary complications are suspected

Management

Immediate priorities are:

• Airway management
• Oxygenation and ventilation
• Suctioning of excessive secretions
• Cardiac monitoring
• Treatment of seizures
• Removal from ongoing exposure

Severe poisoning may require early endotracheal intubation and mechanical ventilation.

Decontamination

For significant dermal contamination:

• Remove contaminated clothing.
• Prevent secondary contamination of healthcare personnel.
• Thoroughly wash exposed skin.

Ocular exposures require irrigation.

Do not induce vomiting.

Older recommendations for routine gastric lavage are no longer standard practice.

Activated charcoal may be considered after selected ingestions when clinically appropriate and when the airway can be safely protected.

Atropine

Atropine is a competitive muscarinic acetylcholine receptor antagonist.

It treats the life-threatening muscarinic manifestations, particularly:

• Bronchorrhea
• Bronchospasm
• Bradycardia

The major therapeutic endpoint in severe poisoning is improvement in pulmonary secretions and ventilation, rather than normalization of pupil size or heart rate.

Severe organophosphate poisoning can require very large cumulative amounts of atropine.

Importantly, atropine does not directly reverse nicotinic neuromuscular weakness.

Pralidoxime (2-PAM)

Pralidoxime is an oxime cholinesterase reactivator.

In organophosphate poisoning, it can reactivate phosphorylated acetylcholinesterase before aging occurs.

It is particularly important for:

• Fasciculations
• Muscle weakness
• Respiratory muscle dysfunction

Its role is strongest in clinically significant organophosphate poisoning. The benefit in carbamate poisoning is less clearly established and depends on the specific exposure.

Seizures

Benzodiazepines are generally used for toxin-induced seizures.

Control of seizures is especially important because prolonged seizures increase:

• Oxygen demand
• Hyperthermia
• Rhabdomyolysis
• Secondary neurologic injury

Delayed Neurologic Syndromes

Organophosphate poisoning can occasionally produce neurologic complications after the initial cholinergic crisis.

Intermediate syndrome

• Develops after the acute cholinergic phase
• Characterized by proximal, neck, cranial, and respiratory muscle weakness

Organophosphate-induced delayed neuropathy

• Occurs later after selected organophosphate exposures
• May produce distal weakness and sensory abnormalities

Thus, apparent resolution of the initial secretory syndrome does not always mean neurologic risk has completely ended.

Key Points

• Cholinergic syndrome results from excess acetylcholine activity.
• Think “wet patient”: salivation, lacrimation, sweating, bronchorrhea, vomiting, diarrhea, and urination.
• Muscarinic effects → secretions, miosis, bronchospasm, bradycardia.
• Nicotinic effects → fasciculations, weakness/paralysis, tachycardia and hypertension.
• Respiratory failure results from a dangerous combination of bronchorrhea + bronchospasm + central depression + neuromuscular weakness.
• Diagnosis is primarily clinical; do not delay treatment while waiting for cholinesterase testing.
• Atropine treats muscarinic toxicity, particularly dangerous pulmonary secretions.
• Pralidoxime reactivates AChE before aging and is especially important in significant organophosphate poisoning.
• Atropine does not reverse nicotinic paralysis.
• Dermal decontamination is particularly important after pesticide exposure because continued skin absorption can prolong toxicity.

Toxicology – Bradypnea

Definition

Bradypnea is an abnormally slow respiratory rate for age. In toxicology, the clinically important issue is not the respiratory rate alone but whether the patient has inadequate ventilation, resulting in hypercapnia, hypoxemia, or inability to protect the airway.

A patient can have a relatively normal respiratory rate but still hypoventilate because the tidal volume is too small.

Pathophysiology

Toxin-associated respiratory depression can result from:

• Depression of the brainstem respiratory center
• Reduced responsiveness to carbon dioxide
• CNS depression with loss of airway protection
• Neuromuscular weakness or paralysis
• Respiratory muscle fatigue

Progressive hypoventilation causes:

CO₂ retention → respiratory acidosis → hypoxemia → cardiovascular/CNS injury → respiratory arrest

Major Toxicologic Causes

Opioids

The classic opioid toxidrome includes:

• Respiratory depression
• CNS depression
• Miosis

Other findings may include:

• Reduced bowel sounds
• Bradycardia
• Hypotension

Key Point: Respiratory depression is the most clinically important feature. Miosis supports the diagnosis but is not always present.

Sedative-Hypnotics

Examples include:

• Benzodiazepines
• Barbiturates
• Ethanol
• Other sedative-hypnotic agents

Typical findings:

• CNS depression
• Slurred speech
• Ataxia
• Reduced respiratory drive in severe poisoning

Isolated benzodiazepine poisoning often causes substantial sedation with relatively preserved respiration; severe respiratory depression should raise concern for coingestants, especially opioids or ethanol.

Clonidine and Imidazolines

These can produce an opioid-like syndrome with:

• CNS depression
• Miosis
• Bradycardia
• Hypotension
• Respiratory depression

Cholinergic Poisoning

Organophosphate and carbamate poisoning can compromise respiration through several simultaneous mechanisms:

• Bronchorrhea
• Bronchospasm
• Central respiratory depression
• Neuromuscular weakness

Associated findings include:

• Miosis
• Salivation
• Lacrimation
• Sweating
• Vomiting and diarrhea
• Fasciculations
• Progressive weakness

Neuromuscular Paralysis

Respiratory failure can also result from paralysis rather than reduced central respiratory drive.

Important examples include:

• Botulism
• Severe organophosphate poisoning
• Tetrodotoxin
• Other neuroparalytic exposures

The patient may remain mentally alert while becoming progressively unable to ventilate.

Nontoxicologic Causes

Important alternatives include:

• Intracranial hemorrhage or other CNS lesions
• Severe hypoglycemia
• Electrolyte or metabolic abnormalities
• Hypothermia
• Neuromuscular disease
• Guillain–Barré syndrome
• Severe pulmonary disease with respiratory muscle exhaustion

A patient who was initially tachypneic and subsequently becomes bradypneic may be developing respiratory fatigue and impending arrest.

Clinical Features

Patients may not recognize their respiratory impairment because altered mental status frequently accompanies toxicologic bradypnea.

Possible findings include:

• Slow or shallow respirations
• Somnolence
• Reduced responsiveness
• Cyanosis
• Hypotension
• Bradycardia in advanced hypoxia
• Inability to protect the airway

Severe hypoventilation can progress rapidly to respiratory arrest.

Pupillary Clues

Miosis

• Opioids
• Clonidine/imidazolines
• Cholinergic poisoning

Dilated pupils

• Severe hypoxia
• Sympathomimetic coexposure
• Antimuscarinic coexposure

Pupil size should therefore be treated as a diagnostic clue rather than a definitive test.

Oxygenation vs. Ventilation

This distinction is especially important.

Pulse oximetry measures oxygenation.

It does not directly measure ventilation or carbon dioxide clearance.

A hypoventilating patient receiving supplemental oxygen can therefore maintain a reassuring oxygen saturation while accumulating dangerous amounts of CO₂.

Assessment may require:

• Respiratory rate and depth
• Mental status
• Pulse oximetry
• Capnography (end-tidal CO₂) when available
• Blood gas analysis in significant or persistent hypoventilation

Evaluation

Initial assessment should focus on:

• Airway patency
• Respiratory rate and depth
• Oxygenation
• Ventilation
• Mental status
• Blood glucose
• Hemodynamic status

Additional investigations may include:

• ECG
• Electrolytes and renal function
• Blood gas
• Chest radiograph when aspiration or pulmonary disease is suspected
• Targeted toxicant concentrations
• Brain imaging when an intracranial cause is possible

Routine urine toxicology screening has important limitations and should not delay treatment.

Management

Airway and ventilation are the immediate priorities.

Management may include:

• Airway positioning and suction
• Supplemental oxygen when hypoxemic
• Assisted ventilation with bag-mask ventilation when needed
• Continuous respiratory monitoring
• Endotracheal intubation and mechanical ventilation when adequate ventilation or airway protection cannot be maintained

Treatment should not be delayed while waiting to identify the exact poison.

Naloxone

Naloxone should be used when opioid-induced respiratory depression is suspected.

The therapeutic goal is restoration of:

• Adequate respiratory rate
• Adequate tidal volume
• Airway protection

Complete awakening is not necessarily required.

Because naloxone may wear off before the opioid does, patients can develop recurrent respiratory depression and require continued monitoring and sometimes repeated therapy.

Naloxone can precipitate acute withdrawal in opioid-dependent patients.

Glucose

Blood glucose should be checked promptly in patients with altered consciousness.

Hypoglycemia should be corrected when present rather than giving dextrose automatically to every patient with depressed mental status.

Decontamination

Do not induce vomiting in a patient with respiratory or CNS depression because aspiration risk is high.

Older references recommended routine gastric lavage in critically poisoned patients. This is not standard modern practice and can substantially increase aspiration and procedural risk.

Activated charcoal should generally be avoided when airway protective reflexes are impaired unless the airway has been appropriately protected and charcoal is otherwise indicated.

Aspiration

Depressed consciousness and loss of airway reflexes increase the risk of aspiration.

Consider aspiration when there is:

• Vomiting
• Hypoxemia
• Coughing
• Abnormal lung examination
• New pulmonary infiltrates

Aspiration can produce chemical pneumonitis and secondary respiratory complications.

Key Points

• Bradypnea is dangerous when it represents inadequate ventilation.
• Respiratory rate alone can underestimate respiratory failure; assess tidal volume and overall ventilation.
• Opioids are a major toxicologic cause of respiratory depression.
• Opioid toxicity classically causes CNS depression + respiratory depression + miosis.
• Clonidine/imidazolines can closely mimic opioid poisoning.
• Cholinergic poisoning can cause respiratory failure through secretions, bronchospasm, central depression, and muscle weakness.
• Pulse oximetry assesses oxygenation but does not exclude hypercapnic hypoventilation.
• Capnography can help detect inadequate ventilation earlier.
• Naloxone is indicated when opioid-related respiratory depression is suspected; the goal is adequate ventilation, not necessarily full consciousness.
• Significant hypoventilation requires immediate airway and ventilatory support.
• A transition from tachypnea to bradypnea in a deteriorating patient may indicate respiratory exhaustion and impending arrest.

Toxicology – Bradycardia Toxidrome

Definition

Bradycardia is a heart rate that is slower than expected for the patient’s age and physiologic condition.

In adults, it is conventionally defined as a resting heart rate <60 beats/min, although the clinical importance depends more on whether the slow rate is causing poor perfusion or hemodynamic instability.

A patient with an asymptomatic slow heart rate and adequate perfusion does not necessarily require treatment.

Pathophysiology

Toxicologic bradycardia can result from several mechanisms:

• β-adrenergic receptor blockade
• Calcium-channel blockade
• Cardiac sodium-channel blockade
• Increased cholinergic activity
• Increased vagal tone
• Suppression of sympathetic outflow
• Direct myocardial depression
• Abnormal cardiac conduction

Nontoxicologic mechanisms include:

• Hypoxia
• Hypothermia
• Hyperkalemia
• Hypermagnesemia
• Myocardial ischemia/infarction
• Increased intracranial pressure

Important Toxicologic Causes

Beta-blockers

• Bradycardia
• Hypotension
• AV block
• Myocardial depression
• CNS depression or seizures with some agents

Severe poisoning can produce cardiogenic shock.

Calcium-channel blockers

• Bradycardia
• Hypotension
• AV block
• Myocardial depression

A useful metabolic clue is hyperglycemia, particularly in severe calcium-channel blocker poisoning.

Digoxin and other cardiac glycosides

• Bradycardia or AV block
• Nausea and vomiting
• Visual disturbances
• Hyperkalemia in significant acute poisoning
• Numerous atrial and ventricular dysrhythmias

Clonidine and imidazolines

• Bradycardia
• Hypotension
• CNS depression
• Miosis
• Respiratory depression

This presentation may resemble opioid poisoning.

Opioids

• CNS depression
• Respiratory depression
• Miosis
• Bradycardia in significant poisoning

Cholinergic agents

Examples include organophosphate and carbamate insecticides.

Typical associated findings include:

• Salivation
• Lacrimation
• Bronchorrhea
• Vomiting and diarrhea
• Urination
• Miosis
• Sweating

Nicotinic manifestations such as fasciculations and muscle weakness particularly support organophosphate/carbamate toxicity.

Other Possible Toxicologic Causes

Bradycardia can also occur with selected exposures involving:

• Baclofen
• Lithium
• Antiarrhythmic drugs
• Certain mushrooms
• Tetrodotoxin
• Saxitoxin
• Other cardiotoxic or neurotoxic agents

The accompanying toxidrome is usually more useful than bradycardia alone for identifying the cause.

Clinical Features

The major question is whether bradycardia is causing inadequate cardiac output.

Concerning findings include:

• Hypotension
• Altered mental status
• Syncope
• Chest discomfort
• Signs of shock
• Pulmonary edema
• Poor peripheral perfusion

Severe poisoning may progress to:

• High-grade AV block
• Ventricular dysrhythmias
• Cardiogenic shock
• Cardiac arrest

Diagnostic Clues

Miosis + respiratory/CNS depression

→ opioid, clonidine, or imidazoline exposure

Bradycardia + hyperglycemia

→ consider calcium-channel blocker toxicity

Bradycardia + hypoglycemia/CNS toxicity

→ may suggest severe beta-blocker poisoning

Bradycardia + vomiting + visual disturbance + hyperkalemia

→ consider digoxin toxicity

Bradycardia + miosis + bronchorrhea + secretions

→ consider cholinergic poisoning

Evaluation

Important investigations include:

• 12-lead ECG
• Continuous cardiac monitoring
• Blood pressure and perfusion assessment
• Pulse oximetry
• Blood glucose
• Electrolytes
• Renal function

Depending on the suspected exposure, additional testing may include:

• Potassium, magnesium and calcium
• Digoxin concentration
• Cholinesterase testing
• Targeted toxicant concentrations
• Acetaminophen concentration when an intentional or unknown overdose is possible

Routine broad urine drug screening is usually less useful than targeted testing based on the clinical toxidrome.

ECG Findings

The ECG helps identify both the severity and possible mechanism.

Possible abnormalities include:

• Sinus bradycardia
• PR prolongation
• AV block
• QRS widening
• QT abnormalities
• Ventricular dysrhythmias

QRS widening should raise concern for an additional sodium-channel-blocking effect rather than simple sinus-node suppression alone.

Management

Treatment is determined by perfusion and underlying cause, not simply by the heart-rate number.

Initial priorities include:

• Airway and ventilation when required
• IV access
• Continuous cardiac monitoring
• Correction of hypoxia
• Correction of important electrolyte or glucose abnormalities
• Appropriate IV fluids when hypovolemia is present

Excessive fluid administration should be avoided when significant myocardial depression is suspected.

Atropine

Atropine may be attempted for symptomatic bradycardia, particularly when increased vagal activity or AV-nodal dysfunction contributes.

However, atropine may be ineffective in severe toxicologic bradycardia, especially with major beta-blocker or calcium-channel blocker poisoning.

Failure of atropine should prompt treatment directed at the responsible toxicant rather than repeated reliance on atropine alone.

Cause-Specific Therapy

Beta-blocker poisoning

• Supportive cardiovascular care
• Vasopressors when necessary
• High-dose insulin euglycemia therapy for severe cardiotoxicity
• Glucagon may be considered, although contemporary practice generally regards it as an adjunct rather than the central therapy.

Calcium-channel blocker poisoning

• IV calcium
• High-dose insulin euglycemia therapy
• Vasopressor support
• Additional rescue therapies in refractory cases

Digoxin toxicity

• Digoxin immune Fab for severe poisoning

Opioid toxicity

• Naloxone when clinically significant respiratory depression is present
• Ventilatory support when necessary

Organophosphate/carbamate toxicity

• Atropine for clinically important muscarinic manifestations
• Pralidoxime is particularly relevant to significant organophosphate poisoning.

Refractory Bradycardia and Shock

When severe bradycardia remains associated with inadequate perfusion despite initial treatment, management may require:

• Vasopressors
• Toxicant-specific antidotal therapy
• Temporary cardiac pacing in selected cases
• Advanced mechanical circulatory support for refractory cardiogenic shock

Importantly, electrical pacing may restore the heart rate without adequately correcting drug-induced myocardial contractile failure, so the underlying poisoning must still be treated.

Decontamination

Older sources recommended routine gastric lavage for poisoned patients with bradycardia. This is not standard modern management.

Activated charcoal may be considered after selected recent ingestions when:

• The substance is adsorbed by charcoal.
• The expected benefit is meaningful.
• The airway is intact or protected.

Decontamination should never delay stabilization of an unstable patient.

Key Points

• Treat symptomatic bradycardia and poor perfusion, not the heart-rate number alone.
• Major toxicologic causes include beta-blockers, calcium-channel blockers, digoxin, clonidine/imidazolines, opioids, and cholinergic agents.
• Bradycardia + hyperglycemia → think calcium-channel blocker toxicity.
• Bradycardia + hypoglycemia/CNS effects → consider beta-blocker toxicity.
• Bradycardia + GI/visual symptoms + hyperkalemia → think digoxin.
• Bradycardia + miosis + respiratory depression → think opioids or clonidine/imidazolines.
• Bradycardia + bronchorrhea/secretions → think cholinergic poisoning.
• Atropine can be attempted in symptomatic bradycardia but may be ineffective in severe cardiotoxic poisoning.
• Severe beta-blocker and calcium-channel blocker poisoning often requires high-dose insulin therapy plus hemodynamic support.
• ECG and continuous cardiac monitoring are essential in clinically significant toxicologic bradycardia.

Toxicology – Body Packers and Body Stuffers

Definitions

A body packer deliberately conceals multiple drug packets within the gastrointestinal tract or another body cavity for transportation or concealment. The packets are usually carefully wrapped and may contain a large total quantity of drug.

A body stuffer hastily swallows or conceals drugs, typically to avoid discovery. Packaging is generally less secure, making leakage more likely, although the total quantity concealed is usually smaller.

This distinction matters clinically:

• Body packer → larger drug burden, better packaging, but packet rupture can cause catastrophic poisoning.
• Body stuffer → smaller burden but poorer packaging and greater likelihood of early leakage.

Pathophysiology

Complications arise through two major mechanisms:

Drug toxicity

• Leakage or rupture releases the packet contents.
• Clinical findings depend on the concealed drug.
• A ruptured body-packer packet can release a very large amount and cause rapidly life-threatening toxicity.

Mechanical complications

• Bowel obstruction
• GI perforation
• Local tissue injury
• Rarely ischemia or other surgical complications

Abrupt deterioration in a known or suspected body packer should raise immediate concern for packet rupture.

Commonly Concealed Drugs

Historically common substances include:

• Cocaine
• Heroin and other opioids
• Amphetamines
• MDMA
• Cannabis products

The clinical toxidrome depends on the actual substance and possible adulterants.

Clinical Features

An asymptomatic patient may remain well while packets are intact.

Symptoms can arise from either drug leakage or GI complications.

Stimulant leakage may cause:

• Agitation
• Tachycardia
• Hypertension
• Hyperthermia
• Mydriasis
• Seizures
• Dysrhythmias
• Severe cardiovascular or neurologic complications

Opioid leakage may cause:

• CNS depression
• Miosis
• Bradypnea
• Hypoventilation
• Respiratory arrest

Mechanical complications may cause:

• Abdominal pain
• Vomiting
• Abdominal distension
• Tenderness
• Reduced bowel sounds
• Features of obstruction or perforation

Severe Complications

Major complications include:

• Respiratory failure
• Seizures
• Hyperthermia
• Rhabdomyolysis
• Acute kidney injury
• Dysrhythmias
• Myocardial ischemia
• Bowel obstruction
• GI perforation
• Shock

A symptomatic body packer requires urgent evaluation and surgical consultation because packet rupture can produce overwhelming drug exposure.

Diagnosis

Diagnosis combines:

• History and circumstances
• Clinical examination
• Identification of the toxidrome
• Appropriate imaging

Routine urine drug screening is not reliable for determining whether packets are present and cannot establish packet number or integrity.

Imaging

Body Packers

Modern evaluation generally favors CT of the abdomen/pelvis without oral or rectal contrast when accurate packet detection is required.

CT is substantially more sensitive than plain abdominal radiography for detecting concealed packets and associated complications.

Plain abdominal radiographs may show packets but can miss them, particularly with modern packaging techniques.

Body Stuffers

Routine imaging is less useful because:

• Packets are smaller.
• Fewer packets are usually present.
• Improvised packaging may be difficult to visualize.

Imaging is particularly important when obstruction, perforation, or another surgical complication is suspected.

Management

Initial management follows standard toxicologic priorities:

• Airway and ventilation
• Circulatory support
• Cardiac monitoring when indicated
• Temperature management
• Treatment of seizures and agitation
• Recognition of the specific toxidrome

Clinical deterioration should be treated immediately rather than waiting for confirmation of packet rupture.

Gastrointestinal Management

Do not induce vomiting.

Manipulation that could rupture a packet should generally be avoided.

For an asymptomatic body packer with intact packets, whole-bowel irrigation with polyethylene glycol electrolyte solution may be considered under specialist supervision to facilitate packet passage.

Activated charcoal may have a role in selected cases, particularly when packet leakage is suspected and the substance is charcoal-adsorbable, but it is not a substitute for definitive management of packet rupture or obstruction.

Routine endoscopic retrieval of GI packets is generally avoided because manipulation can rupture them. Management should be individualized with toxicology, gastroenterology, and surgical input when packets fail to progress or are in anatomically unusual locations.

Packet Rupture or GI Complications

Urgent surgical involvement is required when there is:

• Suspected packet rupture with severe toxicity
• Bowel obstruction
• GI perforation
• Significant bleeding or ischemia
• Failure of packets to progress when clinically concerning

A ruptured packet containing a highly potent drug can cause rapidly fatal poisoning, so supportive resuscitation and definitive management occur simultaneously.

Opioid Toxicity

When opioid leakage produces respiratory depression:

• Naloxone is the specific antagonist.
• Repeated administration or continuous infusion may be necessary when opioid exposure persists.
• Ventilatory support is essential when adequate ventilation cannot otherwise be maintained.

The goal of naloxone is restoration of adequate breathing, rather than necessarily complete arousal.

Stimulant Toxicity

Cocaine or amphetamine leakage may produce severe sympathomimetic toxicity.

Management centers on:

• Benzodiazepines for agitation and seizures
• Aggressive external cooling for severe hyperthermia
• Cardiovascular supportive care
• Management of complications such as rhabdomyolysis

Observation

Body packers generally require monitored medical management until packet passage has been adequately confirmed and the patient remains clinically stable.

Body stuffers usually have fewer packets but may develop toxicity sooner because of poor packaging. Observation requirements depend on the substance, packaging, symptoms, and circumstances.

Key Points

• Body packer = carefully packaged, large total drug quantity, catastrophic consequences if a packet ruptures.
• Body stuffer = hurried concealment, poorer packaging, usually smaller drug quantity and earlier leakage risk.
• Sudden deterioration in a body packer should strongly suggest packet rupture.
• Abdominal pain or vomiting raises concern for obstruction or perforation.
• CT is generally more sensitive than plain radiography for detecting body-packer packets.
• Routine urine drug screening cannot reliably exclude concealed packets.
• Do not induce vomiting or routinely manipulate packets endoscopically.
• Whole-bowel irrigation may be used for selected asymptomatic body packers with intact packets.
• Opioid leakage → respiratory support + naloxone.
• Stimulant leakage → supportive care, benzodiazepines, cooling, and treatment of cardiovascular complications.
• Severe toxicity or a surgical abdominal complication requires urgent multidisciplinary management.

Toxicology – The Initially Asymptomatic Patient

Definition

A patient may initially appear completely well after a potentially serious toxic exposure. Some poisons have latent periods before major clinical effects develop, while others have delayed absorption, delayed formation of toxic metabolites, or delayed organ injury.

Therefore:

Asymptomatic now ≠ nontoxic exposure.

Why Toxicity May Be Delayed

Delayed toxicity can occur because of:

• Slow or prolonged absorption
• Sustained/extended-release formulations
• Formation of toxic metabolites
• Delayed cellular or organ injury
• Enterohepatic recirculation
• Coingestion that delays metabolism
• Initially intact drug packets that later rupture
• Toxic effects that require depletion of physiologic reserves

The expected observation period therefore depends on the specific toxicant, formulation, dose, time of exposure, and patient factors.

Important Exposures with Delayed Toxicity

Acetaminophen

Patients may initially have few or nonspecific symptoms despite a potentially hepatotoxic exposure.

Later findings can include:

• Nausea and vomiting
• Right-upper-quadrant discomfort
• Increasing aminotransferases
• Hepatic failure in severe cases
• Occasionally renal or pancreatic injury

Key Point: Do not use absence of early symptoms to exclude significant acetaminophen toxicity. Risk assessment depends heavily on the timed serum acetaminophen concentration and exposure history.

Anticoagulants / Long-Acting Anticoagulant Rodenticides

Coagulation abnormalities and bleeding may be delayed.

Possible manifestations include:

• Epistaxis
• Gingival bleeding
• Hematuria
• GI bleeding
• Easy bruising

Long-acting anticoagulant rodenticides can produce particularly prolonged coagulopathy.

Arsenic and Thallium

Acute large exposures often cause early GI symptoms, but repeated or smaller exposures may produce delayed systemic manifestations.

Arsenic

• Painful peripheral neuropathy
• Skin changes
• Weakness

Thallium

• Painful neuropathy
• Alopecia
• Neurologic abnormalities

Delayed toxicity may evolve over days to weeks.

Body Packers

Patients carrying internally concealed drug packets may initially be asymptomatic while the packages remain intact.

Packet leakage or rupture can cause sudden, severe poisoning determined by the substance contained within the packet.

This is a high-risk situation because each packet may contain a substantial quantity of drug.

Button Batteries

An esophageal button battery can produce severe tissue injury before obvious symptoms develop.

Modern understanding emphasizes that injury is caused mainly by generation of an electrical current and local hydroxide production, rather than simply leakage of caustic battery contents.

Key Point: Suspected esophageal button-battery impaction is an emergency and should not be managed according to the patient’s apparent lack of symptoms.

Diphenoxylate/Atropine

Toxicity can be delayed, particularly after significant pediatric exposure.

Possible later findings include:

• CNS depression
• Respiratory depression
• Opioid manifestations
• Antimuscarinic findings from atropine

Ethylene Glycol

Early intoxication can resemble ethanol exposure or appear relatively mild.

As toxic metabolites accumulate, patients may develop:

• High-anion-gap metabolic acidosis
• Tachypnea
• Cardiovascular instability
• Hypocalcemia
• Acute kidney injury

Coingested ethanol can delay toxicity because it competes for alcohol dehydrogenase.

Hydrofluoric Acid

Dilute dermal exposures may initially look minor while deeper tissue injury develops.

Later manifestations can include:

• Severe pain
• Progressive tissue injury
• Hypocalcemia
• Hypomagnesemia
• Ventricular dysrhythmias after significant systemic exposure

The severity of pain can be disproportionate to the initial skin appearance.

Lead

Significant exposure may initially be subtle.

Subsequent manifestations can include:

• Abdominal symptoms
• Anemia
• Neurologic abnormalities
• Encephalopathy in severe poisoning

Methanol

Patients may have an initial latent period before toxic metabolites accumulate.

Later manifestations include:

• High-anion-gap metabolic acidosis
• Headache
• Altered mental status
• Visual disturbances
• Severe visual injury
• Coma in severe cases

Ethanol coingestion can delay toxicity by competing for alcohol dehydrogenase.

Methylene Chloride

Methylene chloride is metabolized partly to carbon monoxide.

Consequently, carboxyhemoglobin concentrations and CO-related toxicity may persist or become apparent after the original exposure has ended.

Mercury

Certain organic mercury compounds can have a long latent period before neurologic toxicity becomes clinically apparent.

Potential manifestations include:

• Sensory disturbances
• Ataxia
• Visual or auditory abnormalities
• Other neurologic dysfunction

Monoamine Oxidase Inhibitors (MAOIs)

Significant overdose may initially appear deceptively mild.

Delayed toxicity can include:

• Agitation
• Hyperthermia
• Hypertension or hypotension
• Tachycardia
• Rigidity
• Seizures
• Coma

Significant MAOI overdose therefore requires prolonged clinical observation.

Hepatotoxic Mushrooms

Certain amatoxin-containing mushrooms, particularly Amanita species, can produce a characteristic delayed syndrome.

Typical course:

1. Initial latent period
2. Severe vomiting and diarrhea
3. Apparent temporary improvement
4. Progressive hepatic injury or liver failure

Key Point: GI symptoms beginning more than about 6 hours after mushroom ingestion raise concern for potentially serious mushroom poisoning, although timing alone does not establish the species or toxin.

Naphthalene

Hemolysis may be delayed after exposure.

Possible findings include:

• Weakness
• Abdominal symptoms
• Jaundice
• Dark urine
• Anemia

Patients with G6PD deficiency are particularly susceptible to oxidant-induced hemolysis.

Sulfonylureas and Other Insulin Secretagogues

Hypoglycemia may be delayed and can recur.

Manifestations include:

• Sweating
• Tremor
• Confusion
• Behavioral changes
• Seizures
• Coma

Long-acting preparations and pediatric exposures can require prolonged glucose monitoring.

Quinine

Toxicity can include delayed:

• Visual impairment
• Tinnitus
• CNS effects
• Hypotension
• Cardiac conduction abnormalities and dysrhythmias

Snake Envenomation

Some envenomations may initially produce few findings.

Depending on the species, delayed effects can include:

• Progressive swelling and pain
• Ecchymosis
• Coagulopathy
• Neurotoxicity
• Weakness or paralysis

Absence of immediate symptoms does not reliably exclude clinically important envenomation.

Sustained-Release / Extended-Release Drugs

Modified-release preparations can produce delayed and prolonged absorption.

Potentially important examples include extended-release formulations of:

• Calcium-channel blockers
• Beta-blockers
• Lithium
• Theophylline
• Salicylates

The manifestations depend on the specific drug.

Key Point: Standard observation periods appropriate for immediate-release drugs may be inadequate after extended-release ingestion.

Assessment

For an asymptomatic patient with a potentially serious exposure, determine:

• Exact substance
• Formulation: immediate vs. extended release
• Estimated amount
• Time of exposure
• Route
• Coingestants
• Relevant medical conditions
• Whether delayed toxicity is characteristic of the substance

Investigations should be toxin-specific, rather than relying on a routine broad drug screen.

Examples may include:

• ECG
• Glucose
• Electrolytes and renal function
• Acid-base assessment
• Acetaminophen concentration
• Salicylate concentration
• Coagulation studies
• Other targeted toxicant concentrations

Observation and Disposition

A patient should not be considered safe for discharge solely because the initial examination is normal.

The appropriate observation period depends on:

• Toxicant
• Dose
• Formulation
• Expected toxicokinetics
• Laboratory findings
• Development of symptoms

Some exposures require serial laboratory measurements or prolonged monitoring despite an initially normal examination.

Key Points

• Absence of symptoms does not exclude serious poisoning.
• Acetaminophen can cause major hepatic injury despite minimal early symptoms.
• Methanol and ethylene glycol become more dangerous as toxic metabolites accumulate.
• Extended-release formulations can substantially delay toxicity.
• Amatoxin mushroom poisoning may have a deceptive latent period followed by GI illness and later hepatic failure.
• Button batteries can cause severe esophageal injury before symptoms become obvious.
• Sulfonylurea-induced hypoglycemia can be delayed and recurrent.
• Body-packet rupture can convert an asymptomatic presentation into catastrophic toxicity.
• Observation and testing should be based on the specific exposure, not simply on how well the patient initially appears.

Toxicology – The Initially Asymptomatic Patient

Definition

A patient may initially appear completely well after a potentially serious toxic exposure. Some poisons have latent periods before major clinical effects develop, while others have delayed absorption, delayed formation of toxic metabolites, or delayed organ injury.

Therefore:

Asymptomatic now ≠ nontoxic exposure.

Why Toxicity May Be Delayed

Delayed toxicity can occur because of:

• Slow or prolonged absorption
• Sustained/extended-release formulations
• Formation of toxic metabolites
• Delayed cellular or organ injury
• Enterohepatic recirculation
• Coingestion that delays metabolism
• Initially intact drug packets that later rupture
• Toxic effects that require depletion of physiologic reserves

The expected observation period therefore depends on the specific toxicant, formulation, dose, time of exposure, and patient factors.

Important Exposures with Delayed Toxicity

Acetaminophen

Patients may initially have few or nonspecific symptoms despite a potentially hepatotoxic exposure.

Later findings can include:

• Nausea and vomiting
• Right-upper-quadrant discomfort
• Increasing aminotransferases
• Hepatic failure in severe cases
• Occasionally renal or pancreatic injury

Key Point: Do not use absence of early symptoms to exclude significant acetaminophen toxicity. Risk assessment depends heavily on the timed serum acetaminophen concentration and exposure history.

Anticoagulants / Long-Acting Anticoagulant Rodenticides

Coagulation abnormalities and bleeding may be delayed.

Possible manifestations include:

• Epistaxis
• Gingival bleeding
• Hematuria
• GI bleeding
• Easy bruising

Long-acting anticoagulant rodenticides can produce particularly prolonged coagulopathy.

Arsenic and Thallium

Acute large exposures often cause early GI symptoms, but repeated or smaller exposures may produce delayed systemic manifestations.

Arsenic

• Painful peripheral neuropathy
• Skin changes
• Weakness

Thallium

• Painful neuropathy
• Alopecia
• Neurologic abnormalities

Delayed toxicity may evolve over days to weeks.

Body Packers

Patients carrying internally concealed drug packets may initially be asymptomatic while the packages remain intact.

Packet leakage or rupture can cause sudden, severe poisoning determined by the substance contained within the packet.

This is a high-risk situation because each packet may contain a substantial quantity of drug.

Button Batteries

An esophageal button battery can produce severe tissue injury before obvious symptoms develop.

Modern understanding emphasizes that injury is caused mainly by generation of an electrical current and local hydroxide production, rather than simply leakage of caustic battery contents.

Key Point: Suspected esophageal button-battery impaction is an emergency and should not be managed according to the patient’s apparent lack of symptoms.

Diphenoxylate/Atropine

Toxicity can be delayed, particularly after significant pediatric exposure.

Possible later findings include:

• CNS depression
• Respiratory depression
• Opioid manifestations
• Antimuscarinic findings from atropine

Ethylene Glycol

Early intoxication can resemble ethanol exposure or appear relatively mild.

As toxic metabolites accumulate, patients may develop:

• High-anion-gap metabolic acidosis
• Tachypnea
• Cardiovascular instability
• Hypocalcemia
• Acute kidney injury

Coingested ethanol can delay toxicity because it competes for alcohol dehydrogenase.

Hydrofluoric Acid

Dilute dermal exposures may initially look minor while deeper tissue injury develops.

Later manifestations can include:

• Severe pain
• Progressive tissue injury
• Hypocalcemia
• Hypomagnesemia
• Ventricular dysrhythmias after significant systemic exposure

The severity of pain can be disproportionate to the initial skin appearance.

Lead

Significant exposure may initially be subtle.

Subsequent manifestations can include:

• Abdominal symptoms
• Anemia
• Neurologic abnormalities
• Encephalopathy in severe poisoning

Methanol

Patients may have an initial latent period before toxic metabolites accumulate.

Later manifestations include:

• High-anion-gap metabolic acidosis
• Headache
• Altered mental status
• Visual disturbances
• Severe visual injury
• Coma in severe cases

Ethanol coingestion can delay toxicity by competing for alcohol dehydrogenase.

Methylene Chloride

Methylene chloride is metabolized partly to carbon monoxide.

Consequently, carboxyhemoglobin concentrations and CO-related toxicity may persist or become apparent after the original exposure has ended.

Mercury

Certain organic mercury compounds can have a long latent period before neurologic toxicity becomes clinically apparent.

Potential manifestations include:

• Sensory disturbances
• Ataxia
• Visual or auditory abnormalities
• Other neurologic dysfunction

Monoamine Oxidase Inhibitors (MAOIs)

Significant overdose may initially appear deceptively mild.

Delayed toxicity can include:

• Agitation
• Hyperthermia
• Hypertension or hypotension
• Tachycardia
• Rigidity
• Seizures
• Coma

Significant MAOI overdose therefore requires prolonged clinical observation.

Hepatotoxic Mushrooms

Certain amatoxin-containing mushrooms, particularly Amanita species, can produce a characteristic delayed syndrome.

Typical course:

1. Initial latent period
2. Severe vomiting and diarrhea
3. Apparent temporary improvement
4. Progressive hepatic injury or liver failure

Key Point: GI symptoms beginning more than about 6 hours after mushroom ingestion raise concern for potentially serious mushroom poisoning, although timing alone does not establish the species or toxin.

Naphthalene

Hemolysis may be delayed after exposure.

Possible findings include:

• Weakness
• Abdominal symptoms
• Jaundice
• Dark urine
• Anemia

Patients with G6PD deficiency are particularly susceptible to oxidant-induced hemolysis.

Sulfonylureas and Other Insulin Secretagogues

Hypoglycemia may be delayed and can recur.

Manifestations include:

• Sweating
• Tremor
• Confusion
• Behavioral changes
• Seizures
• Coma

Long-acting preparations and pediatric exposures can require prolonged glucose monitoring.

Quinine

Toxicity can include delayed:

• Visual impairment
• Tinnitus
• CNS effects
• Hypotension
• Cardiac conduction abnormalities and dysrhythmias

Snake Envenomation

Some envenomations may initially produce few findings.

Depending on the species, delayed effects can include:

• Progressive swelling and pain
• Ecchymosis
• Coagulopathy
• Neurotoxicity
• Weakness or paralysis

Absence of immediate symptoms does not reliably exclude clinically important envenomation.

Sustained-Release / Extended-Release Drugs

Modified-release preparations can produce delayed and prolonged absorption.

Potentially important examples include extended-release formulations of:

• Calcium-channel blockers
• Beta-blockers
• Lithium
• Theophylline
• Salicylates

The manifestations depend on the specific drug.

Key Point: Standard observation periods appropriate for immediate-release drugs may be inadequate after extended-release ingestion.

Assessment

For an asymptomatic patient with a potentially serious exposure, determine:

• Exact substance
• Formulation: immediate vs. extended release
• Estimated amount
• Time of exposure
• Route
• Coingestants
• Relevant medical conditions
• Whether delayed toxicity is characteristic of the substance

Investigations should be toxin-specific, rather than relying on a routine broad drug screen.

Examples may include:

• ECG
• Glucose
• Electrolytes and renal function
• Acid-base assessment
• Acetaminophen concentration
• Salicylate concentration
• Coagulation studies
• Other targeted toxicant concentrations

Observation and Disposition

A patient should not be considered safe for discharge solely because the initial examination is normal.

The appropriate observation period depends on:

• Toxicant
• Dose
• Formulation
• Expected toxicokinetics
• Laboratory findings
• Development of symptoms

Some exposures require serial laboratory measurements or prolonged monitoring despite an initially normal examination.

Key Points

• Absence of symptoms does not exclude serious poisoning.
• Acetaminophen can cause major hepatic injury despite minimal early symptoms.
• Methanol and ethylene glycol become more dangerous as toxic metabolites accumulate.
• Extended-release formulations can substantially delay toxicity.
• Amatoxin mushroom poisoning may have a deceptive latent period followed by GI illness and later hepatic failure.
• Button batteries can cause severe esophageal injury before symptoms become obvious.
• Sulfonylurea-induced hypoglycemia can be delayed and recurrent.
• Body-packet rupture can convert an asymptomatic presentation into catastrophic toxicity.
• Observation and testing should be based on the specific exposure, not simply on how well the patient initially appears.

Toxicology – Ascending Paralysis

Definition

Ascending paralysis is progressive flaccid weakness beginning in the lower extremities and moving upward toward the trunk and upper extremities. Severe cases can involve bulbar, facial, and respiratory muscles.

Because respiratory weakness can progress rapidly, ascending paralysis should be considered a potential neurologic emergency.

Major Causes

Important causes include:

Nontoxicologic

• Guillain–Barré syndrome (GBS) — the most important common cause
• Acute intermittent porphyria (AIP)
• Spinal cord disease or compression

Toxicologic

• Tick paralysis
• Tetrodotoxin
• Severe arsenic poisoning
• Karwinskia humboldtiana (coyotillo) poisoning
• Selected toxic neuropathies

Other disorders can cause weakness but follow different patterns. For example, botulism classically produces descending rather than ascending paralysis.

Guillain–Barré Syndrome

GBS is an acute immune-mediated peripheral neuropathy.

It commonly follows an infection, particularly:

• Campylobacter jejuni
• Cytomegalovirus
• Epstein–Barr virus
• Other respiratory or gastrointestinal infections

The classic presentation is:

• Symmetric progressive weakness
• Reduced or absent deep-tendon reflexes
• Weakness beginning in the legs
• Relatively mild sensory symptoms

Cranial nerves may also become involved, producing facial or bulbar weakness.

Autonomic dysfunction can cause:

• Tachycardia or bradycardia
• Hypertension or hypotension
• Dysrhythmias
• Urinary retention

Tick Paralysis

Certain ticks produce a neurotoxin capable of causing:

• Progressive symmetric weakness
• Reduced or absent reflexes
• Ascending flaccid paralysis
• Respiratory weakness in severe cases

Sensory function and mental status are generally preserved.

A careful skin and scalp examination for an attached tick is therefore important.

Removal of the causative tick usually leads to improvement, although respiratory support may temporarily be required.

Tetrodotoxin Poisoning

Tetrodotoxin is associated particularly with certain marine animals, including pufferfish.

Mechanism

Tetrodotoxin blocks voltage-gated sodium channels, preventing normal action-potential propagation.

Clinical features can include:

• Perioral and peripheral paresthesias
• Nausea and vomiting
• Weakness
• Dysphagia
• Cranial nerve abnormalities
• Progressive paralysis
• Respiratory failure

Neurologic effects can develop rapidly after significant exposure.

Arsenic

Severe arsenic poisoning can produce a painful sensorimotor peripheral neuropathy.

Early systemic toxicity may include:

• Severe nausea and vomiting
• Abdominal pain
• Profuse diarrhea
• Cardiovascular instability

Neurologic manifestations can later include:

• Painful paresthesias
• Sensory loss
• Reduced reflexes
• Progressive weakness
• Occasionally ascending paralysis

Acute Intermittent Porphyria

AIP can produce a motor neuropathy that occasionally progresses to severe paralysis.

An acute attack may include:

• Severe abdominal pain
• Nausea and vomiting
• Tachycardia
• Hypertension
• Psychiatric or behavioral manifestations
• Peripheral neuropathy
• Motor weakness
• Hyponatremia

Urinary porphobilinogen (PBG) is an important diagnostic test during a suspected acute attack.

Clinical Features

The characteristic neurologic pattern is:

• Symmetric lower-extremity weakness
• Progression toward the trunk and arms
• Reduced or absent reflexes
• Possible mild paresthesias
• Eventual bulbar or facial involvement
• Respiratory muscle weakness in severe disease

The associated symptoms help identify the underlying cause.

Respiratory Assessment

The most immediately dangerous complication is neuromuscular respiratory failure.

Patients require repeated assessment of:

• Respiratory rate and effort
• Oxygenation
• Ability to handle secretions
• Cough strength
• Bulbar function
• Objective respiratory muscle strength, such as serial forced vital capacity and inspiratory pressure measurements

A normal pulse oximetry reading does not reliably exclude impending ventilatory failure, because oxygenation may remain normal until respiratory weakness becomes advanced.

Airway management should therefore be based on the overall clinical trajectory rather than waiting for a single rigid vital-capacity threshold.

Diagnostic Evaluation

Testing is directed toward the suspected cause.

Possible investigations include:

• Electrolytes
• Calcium and magnesium
• Renal function
• ECG and cardiac monitoring
• Blood gas when respiratory failure is suspected
• Serial respiratory function measurements

Additional targeted tests may include:

• Blood lead concentration
• Arsenic testing
• Urinary porphobilinogen for suspected AIP
• Cholinesterase testing when organophosphate poisoning is suspected
• Nerve-conduction studies/electromyography
• Neuroimaging when spinal cord or CNS pathology is possible

GBS Diagnosis

Lumbar puncture classically demonstrates:

Elevated CSF protein with relatively few white blood cells

This is called albuminocytologic dissociation.

However, CSF protein may still be normal early in the illness, so a normal early lumbar puncture does not exclude GBS.

Differential Diagnosis

Important alternatives include:

• GBS
• Tick paralysis
• Tetrodotoxin poisoning
• Acute porphyria
• Severe toxic neuropathy
• Electrolyte abnormalities
• Myasthenia gravis
• Spinal cord disease
• Botulism

Botulism distinction: botulism typically begins with cranial nerve dysfunction and produces symmetric descending paralysis.

Management

The first priority is respiratory and supportive care.

Important measures include:

• Frequent neurologic reassessment
• Close respiratory monitoring
• Cardiac monitoring when autonomic instability is possible
• Early airway support when respiratory or bulbar weakness progresses
• Identification and treatment of the underlying cause

Patients with significant progressive ascending paralysis generally require hospital admission and close monitoring, often in an intensive-care setting.

Cause-Specific Treatment

GBS

• IV immunoglobulin (IVIG) or
• Plasma exchange

Both are established disease-modifying treatments. Corticosteroids alone are not effective treatment for typical GBS.

Tick paralysis

• Locate and completely remove the tick.
• Continue respiratory support when necessary.

AIP

• Remove precipitating factors.
• Provide supportive care.
• Intravenous hemin is the major specific therapy for significant acute attacks.
• Carbohydrate supplementation may be useful in selected mild attacks but should not delay hemin when significant neurologic disease is present.

Heavy-metal poisoning

• Remove the exposure.
• Appropriate chelation may be indicated depending on the metal and severity.

Tetrodotoxin

• No established specific antidote.
• Treatment is primarily meticulous supportive and respiratory care.

Decontamination

Older references recommended routine gastric lavage for some toxic ingestions. This is not standard modern practice.

Activated charcoal may occasionally be considered after an appropriate recent ingestion when the substance is adsorbed by charcoal and the airway is adequately protected.

Decontamination should never delay stabilization of airway, breathing, and circulation.

Key Points

• Ascending paralysis = weakness beginning in the legs and progressing upward.
• GBS is the major common cause and typically produces symmetric weakness with reduced or absent reflexes.
• Tick paralysis can closely resemble GBS; examine the entire skin and scalp.
• Tetrodotoxin blocks voltage-gated sodium channels and can rapidly cause paralysis and respiratory failure.
• Severe arsenic poisoning can produce a painful peripheral neuropathy with progressive weakness.
• Botulism usually causes descending, not ascending, paralysis.
• Albuminocytologic dissociation supports GBS, but it may be absent early.
• Respiratory deterioration can occur before major abnormalities appear on pulse oximetry.
• Progressive bulbar or respiratory weakness requires early airway planning and intensive monitoring.